相似文献
1
Greenhouse Gas Emissions and Costs of Inhaler Devices in the US.
JAMA. 2024 Sep 24;332(12):1017-1019. doi: 10.1001/jama.2024.15331.
2
Downstream Effects of Market Changes on Inhalers: Impacts on Individuals With Chronic Lung Disease.
Respir Care. 2024 Oct 25;69(11):1448-1456. doi: 10.4187/respcare.12024.
3
Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.
Health Technol Assess. 2001;5(26):1-149. doi: 10.3310/hta5260.
4
Out-of-Pocket Prescription Drug Savings for Medicare Beneficiaries with Asthma and COPD Under the Inflation Reduction Act.
J Gen Intern Med. 2025 Apr;40(5):1141-1149. doi: 10.1007/s11606-024-09063-4. Epub 2024 Oct 4.
5
Misuse and/or treatment delivery failure of inhalers among patients with asthma or COPD: A review and recommendations for the conduct of future research.
Respir Med. 2017 Aug;129:98-116. doi: 10.1016/j.rmed.2017.05.004. Epub 2017 May 15.
6
Device errors in asthma and COPD: systematic literature review and meta-analysis.
NPJ Prim Care Respir Med. 2017 Apr 3;27(1):22. doi: 10.1038/s41533-017-0016-z.
7
Outcomes Following Initiation of Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol versus Multiple-Inhaler Triple Therapy Among Medicare Advantage with Part D Beneficiaries and Those Commercially Enrolled for Health Care Insurance in the United States.
Int J Chron Obstruct Pulmon Dis. 2024 Jan 11;19:97-110. doi: 10.2147/COPD.S424497. eCollection 2024.
8
Cost-Effectiveness of Single-Inhaler Versus Multiple-Inhaler Triple Therapy in COPD: A German Healthcare Perspective.
Int J Chron Obstruct Pulmon Dis. 2025 Jun 19;20:2011-2022. doi: 10.2147/COPD.S492524. eCollection 2025.
9
Albuterol and levalbuterol use and spending in Medicare beneficiaries with chronic obstructive pulmonary disease.
Am J Geriatr Pharmacother. 2010 Dec;8(6):571-82. doi: 10.1016/S1543-5946(10)80006-6.
10
New developments in inhaler devices within pharmaceutical companies: A systematic review of the impact on clinical outcomes and patient preferences.
Respir Med. 2015 Nov;109(11):1430-8. doi: 10.1016/j.rmed.2015.09.013. Epub 2015 Sep 30.
引用本文的文献
1
Carbon Footprint Impact, of Monoclonal Antibodies for Severe Asthma, Administered in Italy.
Biomedicines. 2025 Jun 27;13(7):1574. doi: 10.3390/biomedicines13071574.
2
Reducing carbon, enhancing care: the future of sustainable medicine.
Front Pharmacol. 2025 Jul 3;16:1637531. doi: 10.3389/fphar.2025.1637531. eCollection 2025.
3
Budesonide-Formoterol Metered-Dose Inhaler vs Fluticasone-Salmeterol Dry-Powder Inhaler.
JAMA Intern Med. 2025 Jul 7. doi: 10.1001/jamainternmed.2025.2299.
4
Utilization and access to metered-dose inhalers and sustainable alternatives among older adults in the United States: a population-based study.
Lancet Reg Health Am. 2025 Jun 5;47:101142. doi: 10.1016/j.lana.2025.101142. eCollection 2025 Jul.
5
The comparative effectiveness and safety of fluticasone-salmeterol via metered-dose versus dry powder inhalers for COPD: A new user cohort study.
PLoS Med. 2025 May 14;22(5):e1004596. doi: 10.1371/journal.pmed.1004596. eCollection 2025 May.
6
Pragmatic Evaluation of an Improvement Program for People Living With Modifiable High-Risk COPD Versus Usual Care: Protocols for the Cluster Randomized PREVAIL Trial.
Chronic Obstr Pulm Dis. 2025 May 27;12(3):223-239. doi: 10.15326/jcopdf.2024.0564.
7
Implementation of a Metered-Dose Inhaler to Dry-Powder Inhaler National Formulary Transition.
JAMA Netw Open. 2024 Dec 2;7(12):e2449234. doi: 10.1001/jamanetworkopen.2024.49234.
Zotero 插件